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ABSTRACT Mastocytosis can be associated with other clonal or non-
clonal hematologic diseases as well as a variety of non-hematologic 
malignancies. A 75-year-old Caucasian male patient was referred to 
us with a 5-month history of neutrophilic leukocytosis and mild sple-
nomegaly. He had developed a cutaneous melanoma sixteen years 
ago. According to the clinical and pathological features, a final diag-
nosis of systemic mastocytosis was established. the patient started 
treatment with interferon-α at a dose of 3 MiU/day, combined with 
low doses of prednisone. We observed a rapid disappearance of 
symptoms. Unfortunately, after 3 months a diagnosis of pancreatic 
adenocarcinoma was established. A review of the literature suggests 
that mastocytes could have a pivotal role in several malignancies. Dif-
ferent chemokines, mitogenic factors, chemical mediators of inflam-
mation, and specific gene mutations could explain the association 
between mastocytosis and other hematologic and non-hematologic 
disorders.
KEY WORDS: mastocytosis, melanoma, pancreatic neoplasms, trypt-
ases
INTRODUCTION
Mastocytosis includes a group of disorders af-
fecting both children and adults, characterized by an 
exponential proliferation and accumulations of mast 
cells in one or more organs (1). According to the 2008 
WHO classification, mastocytosis is categorized un-
der cutaneous mastocytosis that accounts for about 
90% of cases (with often only a cutaneous localiza-
tion), and systemic mastocytosis (2).
Systemic mastocytosis is characterized by an in-
filtration of clonally derived mast cells in different tis-
sues, including the bone marrow, skin, gastrointesti-
nal tract, liver, bones, lymph nodes, and spleen. the 
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diagnosis is based on the identification of neoplas-
tic mast cells and/or genetic mutations (2,3). At the 
same time, it can be associated with other clonal or 
non-clonal hematologic diseases as well as a variety 
of non-hematologic neoplasms, emphasizing shared 
pathophysiologic mechanisms (1,3). in this regard, 
different etiopathogenetic factors may be involved: 
chemokines (as CCl1, CCl2, CXCl8, CCl3, CCl4, CCl5), 
mitogenic factors (GM-CSF), chemical mediators of 
the inflammation and specific gene mutations; this 
could explain the association between mastocytosis 
and other hematologic and non-hematologic disor-
ders, such as malignant melanoma (MM) and pancre-
atic cancer.
Starting from a clinical observation, we reviewed 
the literature focusing on the role of mast cells in sev-
eral pathogenic processes that can involve different 
cell lineages.
CASE REPORT
A 75-year-old Caucasian male patient was first ad-
mitted to our Hematology Center in April 2012 with 
a 5-month history of neutrophilic leukocytosis (WBC 
15.13 × 109/l; neutrophils 9.76 × 109/l) and mild sple-
nomegaly (15.4 × 15.5 cm). His familial history was 
negative for hematologic diseases and/or malignan-
cies. in his personal medical history, a cutaneous MM 
was removed 16 years earlier (3.5 mm Breslow, ulcer-
ated with iV Clark’s level; pt3b n2a M0, Stage iiiB), for 
which he received treatment with dacarbazine (850 
mg/m2 every 28 days for a total of 6 cycles) and in-
terferon-α (3.000.000 international units [MiU]/day 
× 3 times/weekly for a total of 36 months). Periodic 
clinical and instrumental examinations, performed at 
planned intervals over the years, showed no disease 
recurrence. 
On admission, the clinical examination revealed a 
splenomegaly combined with a mild hepatomegaly; 
no lymphadenopathies were found. the laboratory 
investigations confirmed the neutrophilic leukocyto-
sis (WBC 16.96 × 109/l; neutrophils 11.38 × 109/l; lym-
phocytes 2.54 × 109/l, and monocytes 1.63 × 109/l) 
and mild thrombocytopenia (platelets 109 × 109/l). 
An increase in polyclonal gammaglobulins and eryth-
rocyte sedimentation rate (eSr) was also observed. 
A chronic myeloproliferative disease was suspect-
ed and molecular evaluation of JAK-2 mutations and 
BCr-ABl rearrangement were negative. A cytogenet-
ic analysis was carried out on bone marrow cells, but 
no karyotype abnormalities were detected. A bone 
marrow biopsy showed the presence of granuloblas-
tic hyperplasia, with less than 5% of undifferentiated 
CD34+ progenitor cells and scattered CD20+ and 
Figure 1. Hyper-cellular bone marrow with granuloblastic 
hyperplasia and peri-trabecular areas of fibrosis (hematoxy-
lin-eosin, ×40).
Figure 2. Aggregates of mast cells (asterisks) showing intracytoplasmic metachromatic granules (2a, Giemsa stain, ×100) and 
strong expression of c-kit (2b, ×40). in panel B, the brown color is the positive c-Kit receptor immunostaining.
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CD3+ lymphocytes. Furthermore, focal areas of fibro-
sis were observed around the bone trabeculae (Fig-
ure 1), along with features of increased bone remod-
eling. Parathormon, serum calcium levels, alkaline 
phosphatases, and thyroidal hormone analyses were 
within the normal ranges; a bone scintigraphy high-
lighted unspecific osteo-artopathic features. the total 
body computerized axial tomography confirmed the 
isolated splenomegaly (17 cm × 15 cm) and a mild 
hepatomegaly, without other findings. 
Six months later, because of progressive asthenia 
combined with persistent neutrophilic leukocytosis 
and progressive increase of the spleen (19 × 20 cm) 
a further bone marrow evaluation was performed. 
the second bone biopsy showed a granuloblastic 
hyperplasia with a prevalence of immature MPO+/
CD34- progenitor cells mainly within the inter-tra-
becular space. Multiple peri-trabecular and peri-ve-
nous nodular aggregates of predominantly fusiform 
cells showing metachromatic granules at Giemsa 
staining (Figure 2, a) and C-kit expression (Figure 2, b) 
were also observed. An increase of bone remodeling 
was also present with irregular thinning of the bone 
trabeculae. the serum tryptase level was ≥80 ng/ml. 
Based on the clinical and pathologic features, a final 
diagnosis of systemic mastocytosis was established.  
A treatment with interferon-α at a dose of 3MiU/
day, combined with low doses of prednisone, was 
started. We observed a rapid disappearance of symp-
toms associated with a normalization of the peripher-
al blood values and a reduction of spleen volume. Un-
fortunately, 3 months later the patient experienced a 
worsening abdominal pain. Ultrasonography and 
computed tomography (Ct) revealed a pancreatic le-
sion, involving the surrounding tissues and the celiac 
axis, combined with multiple abdominal lymphade-
nopathies and peritoneal carcinomatosis. A biopsy of 
the pancreatic lesion was diagnostic for a pancreatic 
adenocarcinoma. the patient was in stage iV and was 
treated with the chemotherapy FOlFirinOX regimen 
(fluorouracil/irinotecan and oxaliplatin). Unfortu-
nately, the patient died 5 months after the diagnosis 
of the pancreatic cancer. Because of the absence of 
melanoma recurrence over 16 years and because of 
the absence of nodal involvement by melanoma me-
tastases at the diagnosis of systemic mastocytosis, we 
believe that the patient died due to stage iV pancre-
atic adenocarcinoma.
Figure 3. Physiopathologic pathways between mast cells, pancreatic cells, melanocytes, and neutrophils. CCl1, CCl2 
(blocked by steroids), CCl3, CCl4, CCl5, and CXCl8 chemokines secreted by mast-cells can induce recruitment of the neutro-
phils in tissues, while granulocyte-macrophage colony stimulating factor (GM-CSF), secreted by active mast cells, can deter-
mine neutrophilia. Accordingly,  there is a local inflammation in the skin (cutaneous manifestations of mastocytosis), which 
can result in a high utilization of therapy with psoralen and ultraviolet A therapy (PUVA therapy), with a relative increased 
risk of melanoma. Mast-cells via interleukin (il) 6, 8, 11, 12, basic fibroblast growth factor (b-FGF), hepatocyte growth factor 
(HGF), nerve growth factor (nGF), stem cell factor (SCF), and histamine can determine morpho-structural changes in mela-
nocytes. in addition, both mast-cells and melanocytes express the Kit receptor. Mast-cells orchestrate cancer cell migration 
and proliferation in pancreatic cells (also justified by high levels of serum tryptase in patients with pancreatic cancer, as well 
as a major aggressive course of pancreatic cancers with a high mast cells population in tissue samples). in turn, malignant 
pancreatic cells and melanoma (bottom left) share specific gene alterations such as CDKn2A, CtnnA2, MirG264, 
BrAF, KrAS, and ADAMtS2.
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DISCUSSION
the clinical observation of a patient who devel-
oped three different cancers, one of them derived 
from mastocytes (systemic mastocytosis), stimulated 
us to review the literature, focusing on the role of 
mast cells in different hematologic and non-hemato-
logic diseases.
Mast-cell diseases and hematological 
alterations
in about 40% of cases, systemic mastocytosis is 
associated with other hematologic non-mast cells-re-
lated disorders (2,3). However, sporadic data on neu-
trophilic leukocytosis as prodromal onset of a systemic 
mastocytosis have been reported (1). Few reports are 
available on the pathogenetic role of some chemo-
kines and their receptors, which could be involved 
in various clinical forms of mastocytosis (4). in 2006, 
Homey et al. analyzed the role of CCl1, CCl2, CCl3, 
CCl4, CCl5 (rAnteS), and CXCl8 (il-8) obtained from 
HMC-1 line mast cells (Figure 3) in this study, the au-
thors specifically highlighted how the chemokine CCl2 
differs from the others, as its expression can be signifi-
cantly inhibited with glucocorticoid therapy (5). Other 
chemokines (belonging to the CCl family and MiP-1α) 
are responsible for the recruitment of neutrophils in 
several tissues (including the skin), increasing the in-
flammatory process without inducing a neutrophil 
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F: female; M: male; nr: non reported; nA: not applicable; MStO: mastocytosis; CM: cutaneous mastocytosis; nP: not pro-
vided; MUP: melanoma with unknown primary; CnMlD: clonal hematologic non-mast cell lineage disorder; Same sample: 
the melanocytic lesion and the mast cell disorder were in the same tissue sample; : normal range; : means high levels
Table 1. Benign and malignant melanocytic lesions reported in literature associated with mast cell disorders
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proliferation (Figure 3). Moreover, it has been demon-
strated that the activated mast cells can release GM-
CSF (6), which is the pivotal growth factor required for 
neutrophil expansion (Figure 3). Based on these data, 
it can be assumed that a subset of activated mast 
cells produces GM-CSF (primarily responsible for the 
neutrophilia) and chemokines of the CCl family in 
systemic mastocytosis, which are responsible for the 
recruitment of neutrophils in the skin lesions (in case 
of cutaneous involvement). Our observations sug-
gest that a neutrophil leukocytosis can in some cases 
hide an underlying rare disease.
Mast-cell diseases and benign/malignant 
melanocytic neoplasms
Although MM and mastocytosis arise from two 
different cell types, the occurrence of mastocytosis 
and MM in the same patient might suggests a rela-
tionship between the two disorders (Figure 3). in-
deed, a Swedish paper has reported a higher risk of 
MM in patients with mastocytosis compared with the 
general population (5.0% vs 1.2-1.6%) (7).
Since 1979, a total of 13 patients (9 cases of MM 
and 4 cases of benign melanocytic lesions) with mast 
cell diseases and melanocytic lesions, both benign 
and malignant, have been reported in the literature 
(7-15). With regard to MM (median thickness: 1.02 
mm, range: 0.4-5.6 mm) the diagnosis of MM and 
mastocytosis was synchronous in 1 case, while a di-
agnosis of mastocytosis preceded the one of MM in 4 
cases, and was metachronous in the other 4 cases. Ad-
ditionally, as reported in the table 1, in 5 cases (38%) 
the benign/malignant melanocytic lesions were in 
the same tissue sample of a mast cell proliferation, 
presenting as combined tumors, further confirm-
ing an underlying interdependence between these 
two cell lineages. in fact, the release of chemokines, 
stem cell factors and histamine (via the histamine-2 
(H2) receptor) by mast cells supports the proliferation 
of melanocytes (Figure 3). in this regard, it is known 
that both melanocytes and mastocytes express two 
transcription factors (MitF and StAt3), and that me-
lanocytes are dependent on Kit and its ligand (stem 
cell factor (SCF)) for their growth and development 
(7,8,16). Other important cytokines – such as interleu-
kin (il)-6, il-8, basic fibroblast growth factor (bFGF), 
and nerve growth factor (nGF) – are involved in the 
common pathway of both of these different cellular 
lines (13). Finally, it is known that some treatments, 
e.g. 311 nm ultraviolet B (UVB= and psoralen and ul-
traviolet A (PUVA), usually used for cutaneous masto-
cytosis, may increase the relative risk of developing 
MM (7,13).
recently, Siiskonen et al. reported that the number 
of tryptase+ and chymase+ mast cells is lower in deep-
ly invasive melanomas compared with in-situ mela-
nomas and dysplastic nevi; moreover, a low number 
of the tryptase+ mast cells is associated with a poor 
survival both in deeply invasive melanomas and in su-
perficially invasive melanomas at an advanced stage 
(17). the authors suggest that the serine proteinases 
(tryptase and chymase) may inhibit the melanoma 
growth. However, the authors did not find any signifi-
cant correlation between the number of the tryptase+ 
mast cells and the most important clinic-pathologic 
features (age, sex, Breslow, ulceration, mitoses, micro-
satellites, tumor-infiltrating lymphocytes, regression, 
growth phase, cell type, lymphovascular and/or peri-
neural invasion, and horizontal tumor diameter) (17). 
in summary, while some papers emphasize that 
the infiltration of mast cells in the primary melanoma 
is associated with a better prognosis (17-20), other 
ones show that the infiltration of mast cells is asso-
ciated with invasive melanoma and neo-vasculariza-
tion, favoring the tumor growth (21-23). in this regard, 
since there are currently conflicting data and consid-
ering the versatility of mast cells (17,18), further stud-
ies will be needed to better define the pivotal role of 
the mast cells in the etio-pathogenesis of MM.
Mast-cell diseases and pancreatic cancer
Since Paul ehrich discovered the important role of 
mastocytes in the immune system of the vertebrate 
in the late 1800’s, several other functions have been 
identified for these cells (24), such as their role in the 
gastrointestinal system where they are involved both 
in inflammatory diseases and in the development of 
malignancies. 
regarding pancreatic cancer, it has been shown 
that a mast cell infiltration in the tumor is associated 
with a higher tumor grade and cancer cell migration 
(Figure 3), proliferation, and invasion, with a conse-
quent decrease in the survival of these patients (24-
26).
Histologically, mast cells are contained in the tu-
mor stroma, but not connected with the malignant 
pancreatic cells (26). Comparable findings were also 
detected in MM, where the mast cell infiltration was 
peri-tumoral and not in connection with the melano-
ma cells (13). However, in a recent paper, Giuşcă et al. 
found that (regarding liver metastases from different 
neoplasms) intra-tumor mast cells were significantly 
correlated with tumor grade and nodal status, while 
peri-tumoral mast cells were significantly correlated 
with overall survival (27). Accordingly, it can be as-
sumed that the mast cells influence the tumor cells 
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via cytokine signals. this hypothesis could be also 
confirmed by the presence of elevated serum trypt-
ase activity in patients with a diagnosis of pancreatic 
cell carcinoma (26). Similarly, serum tryptase levels 
correlate with the density of tryptase+ mast cells and 
the microvascular density in breast cancer before 
radical surgery, corroborating the pro-tumoral effects 
of mast cells in angiogenesis promotion (28). in this 
regard, serum tryptase activity could be an important 
biomarker in the monitoring of patients with pancre-
atic cancer as well as those with other malignancies 
(26,27).
Melanoma and pancreatic cancer
the association of MM and pancreatic carcinoma 
is characterized by an increased frequency of CD-
Kn2A mutations in both malignancies (29). However, 
Fidalgo et al. did not find CDKn2A mutations in three 
patients (with both MM and pancreatic carcinoma), 
but rather identified two rare gene mutations (a 616 
kb duplication at 2p12 encompassing the CtnnA2 
and Mir4264 genes and a 368 kb duplication at 
5q35.3 containing the GrM6, ADAMtS2, ZnF879, and 
ZnF354C genes), widening the spectrum of connec-
tions between the two malignancies (24). Finally, in 
a very recent report, Heestand et al. identified BrAF 
and KrAS mutations in patients with pancreatic car-
cinoma, suggesting their pivotal role in the pathoge-
netic mechanism of this malignancy (29) (Figure 3). 
the encoded Kit protein is a transmembrane 
protein belonging to the family of type iii receptors, 
tyrosine kinases, and plays an important role in the 
development of hematopoietic stem cells, mast cells, 
melanocytes, germ cells, and interstitial cells of Cajal 
(30). the role of Kit signaling in melanocyte biology 
has been extensively studied, and the regulation of 
the Kit pathway is complex, depending on multiple 
cellular factors (31,32). Currently, genetic mutations 
of Kit have been detected in mucosal (39%) and acral 
(36%) melanomas and in skin with sun-induced dam-
age (28%) (32), but not in the less-investigated pan-
creatic cancer. 
it has been demonstrated that Kit protein is in-
volved in mediating differentiation and proliferation 
of pancreatic islets during fetal pancreatic develop-
ment (33); however, no conclusive data on the role 
of Kit in the development of pancreatic ductal ad-
enocarcinoma are available (34). Amsterdam et al. 
demonstrated that Kit expression is negative in the 
pancreatic cells of healthy adults, whereas it becomes 
positive in the cancerous pancreatic cells (35). these 
results suggest mutational events which lead to the 
malignant transformation of pancreatic cells.
CONCLUSION
As suggested by the literature data, mast cells can 
modulate different normal and abnormal cells via 
cytokine signals. Mastocytes seem to have a pivotal 
role in several malignancies (such as in melanoma 
and pancreatic cancer) and serum tryptase levels 
could be an important prognostic factor. Moreover, 
different chemokines, mitogenic factors, chemical 
mediators of the inflammation, and specific gene mu-
tations could explain the association between masto-
cytosis and other hematologic and non-hematologic 
disorders.
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